🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

ARS Pharmaceuticals, Inc.

SPRY Healthcare
$8.3 +$0.19 (2.34%)
Market Cap: $824.17 M
Gurus Holding
2
Popularity Rank
#3692
% of Shares Held
0.77%
Net Activity (Q4 2025)
+$7.41 M

Guru Ownership Trend

Guru Analysis for ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals, Inc. (SPRY), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q4 2025, a total of 2 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $6.34 M.

Top institutional holders include Daniel Loeb and Chuck Royce.

Institutional sentiment is currently Bullish. This is evidenced by a $7.41 M net inflow during the quarter.

Recent activity highlights Daniel Loeb who opened a new position.

Key Holders

Top 5 by Value

$6.48 M
$2.41 M

Top 5 by Conviction

0.09%
0.02%

Recent Activity Breakdown (Q4 2025)

+$8.89 M
Total Buy Value
New Buys 2
Additions 0
-$1.48 M
Total Sell Value
Reductions 0
Sold Out 1

Guru Consensus (Q4 2025)

Based on recent activity
Net Sellers
1
Net Buyers
2

FAQs for ARS Pharmaceuticals, Inc. (SPRY)

Major holders include Daniel Loeb ($6.48 M), Chuck Royce ($2.41 M). According to the latest reported data, 2 tracked investment managers collectively hold approximately 763,288 shares.

According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $7.41 M, with 2 managers increasing positions and 1 managers reducing holdings.

During the most recent reporting period, 0 managers trimmed their positions, while 1 fully exited SPRY. The total reported sell value was $1.48 M.

Yes, 2 managers opened new positions in SPRY, and 0 increased their existing holdings. The total reported buy value was $8.89 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.09% New Buy 556,237 $6.48 M Q4 2025
0.02% New Buy 207,051 $2.41 M Q4 2025
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form